Engineered patient T cells using chimeric antigen receptors (CAR-Ts) are a great invention from the last decade, eradicating tumors and providing durable remissions. However, first generation CAR-Ts require shipment of cryopreserved cells to large factories and labor-intensive manual processing, as designed in the ’90s.
It takes 1-2 months while patients can not wait due to cancer progression.
T cells don’t like freezing and lengthy processing outside the body.
It also takes > 300,000 USD/EUR per treatment, limiting wide patient access.
At CellPoint, we designed an unconventional CAR-T manufacturing and supply model using the best technology.
CellPoint will disrupt time-to-treatment and costs completely
Our Vision & mission
CD19 CAR-T
60,000 + patients in need yearly
BCMA CAR-T
40,000 + patients in need yearly
Plug and play
Follow up CARs in development
Low costs
Point-of-care supply will drop costs per treatment